Role of radiotherapy for pancreatobiliary neuroendocrine tumors

Jeongshim Lee, Jinhyun Choi, Chihwan Choi, Jinsil Seong

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: We investigated the role of radiotherapy (RT) for pancreatobiliary neuroendocrine tumors (PB-NETs). Materials and Methods: We identified 9 patients with PB-NETs who received RT between January 2005 and March 2012. Of these 9 patients, 4 were diagnosed with NETs in the pancreas and 5 were diagnosed with NETs in the gallbladder. All patients received RT to the primary tumor or resection bed with a median total irradiation dose of 50.4 Gy, with or without chemotherapy. Results: The tumor response rate and tumor control rate in the RT field were 60% and 100 %, respectively. All 4 patients who underwent surgery had no evidence of disease in the RT field. Of the 5 patients who received RT to the primary gross tumor, 1 had complete response, 2 had partial response, and 2 had stable disease in the RT field. The median time to progression was 11 months. Of the 9 patients, four patients had no progression, and 5 patients had progression of disease (locoregional, 2; distant, 2; locoregional/distant, 1). Of the 4 patients without progression, 3 were treated with RT in adjuvant or neoadjuvant setting, and one received RT to primary tumor. One patient experienced radiation-induced duodenitis at 3 months after concurrent chemoradiation without treatment-related mortality. Conclusion: RT can yield local control for advanced PB-NETs. RT should be considered an essential part of multimodality treatment in management of advanced PB-NETs.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalRadiation Oncology Journal
Volume31
Issue number3
DOIs
Publication statusPublished - 2013 Sep 1

Fingerprint

Neuroendocrine Tumors
Radiotherapy
Neoplasms
Duodenitis
Adjuvant Radiotherapy
Gallbladder
Disease Progression
Pancreas
Radiation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Lee, Jeongshim ; Choi, Jinhyun ; Choi, Chihwan ; Seong, Jinsil. / Role of radiotherapy for pancreatobiliary neuroendocrine tumors. In: Radiation Oncology Journal. 2013 ; Vol. 31, No. 3. pp. 125-130.
@article{6cb416ffaa864ca1936f2ac526c2be25,
title = "Role of radiotherapy for pancreatobiliary neuroendocrine tumors",
abstract = "Purpose: We investigated the role of radiotherapy (RT) for pancreatobiliary neuroendocrine tumors (PB-NETs). Materials and Methods: We identified 9 patients with PB-NETs who received RT between January 2005 and March 2012. Of these 9 patients, 4 were diagnosed with NETs in the pancreas and 5 were diagnosed with NETs in the gallbladder. All patients received RT to the primary tumor or resection bed with a median total irradiation dose of 50.4 Gy, with or without chemotherapy. Results: The tumor response rate and tumor control rate in the RT field were 60{\%} and 100 {\%}, respectively. All 4 patients who underwent surgery had no evidence of disease in the RT field. Of the 5 patients who received RT to the primary gross tumor, 1 had complete response, 2 had partial response, and 2 had stable disease in the RT field. The median time to progression was 11 months. Of the 9 patients, four patients had no progression, and 5 patients had progression of disease (locoregional, 2; distant, 2; locoregional/distant, 1). Of the 4 patients without progression, 3 were treated with RT in adjuvant or neoadjuvant setting, and one received RT to primary tumor. One patient experienced radiation-induced duodenitis at 3 months after concurrent chemoradiation without treatment-related mortality. Conclusion: RT can yield local control for advanced PB-NETs. RT should be considered an essential part of multimodality treatment in management of advanced PB-NETs.",
author = "Jeongshim Lee and Jinhyun Choi and Chihwan Choi and Jinsil Seong",
year = "2013",
month = "9",
day = "1",
doi = "10.3857/roj.2013.31.3.125",
language = "English",
volume = "31",
pages = "125--130",
journal = "Radiation Oncology Journal",
issn = "2234-1900",
publisher = "Korean Society for Therapeutic Radiology and Oncology",
number = "3",

}

Role of radiotherapy for pancreatobiliary neuroendocrine tumors. / Lee, Jeongshim; Choi, Jinhyun; Choi, Chihwan; Seong, Jinsil.

In: Radiation Oncology Journal, Vol. 31, No. 3, 01.09.2013, p. 125-130.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of radiotherapy for pancreatobiliary neuroendocrine tumors

AU - Lee, Jeongshim

AU - Choi, Jinhyun

AU - Choi, Chihwan

AU - Seong, Jinsil

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Purpose: We investigated the role of radiotherapy (RT) for pancreatobiliary neuroendocrine tumors (PB-NETs). Materials and Methods: We identified 9 patients with PB-NETs who received RT between January 2005 and March 2012. Of these 9 patients, 4 were diagnosed with NETs in the pancreas and 5 were diagnosed with NETs in the gallbladder. All patients received RT to the primary tumor or resection bed with a median total irradiation dose of 50.4 Gy, with or without chemotherapy. Results: The tumor response rate and tumor control rate in the RT field were 60% and 100 %, respectively. All 4 patients who underwent surgery had no evidence of disease in the RT field. Of the 5 patients who received RT to the primary gross tumor, 1 had complete response, 2 had partial response, and 2 had stable disease in the RT field. The median time to progression was 11 months. Of the 9 patients, four patients had no progression, and 5 patients had progression of disease (locoregional, 2; distant, 2; locoregional/distant, 1). Of the 4 patients without progression, 3 were treated with RT in adjuvant or neoadjuvant setting, and one received RT to primary tumor. One patient experienced radiation-induced duodenitis at 3 months after concurrent chemoradiation without treatment-related mortality. Conclusion: RT can yield local control for advanced PB-NETs. RT should be considered an essential part of multimodality treatment in management of advanced PB-NETs.

AB - Purpose: We investigated the role of radiotherapy (RT) for pancreatobiliary neuroendocrine tumors (PB-NETs). Materials and Methods: We identified 9 patients with PB-NETs who received RT between January 2005 and March 2012. Of these 9 patients, 4 were diagnosed with NETs in the pancreas and 5 were diagnosed with NETs in the gallbladder. All patients received RT to the primary tumor or resection bed with a median total irradiation dose of 50.4 Gy, with or without chemotherapy. Results: The tumor response rate and tumor control rate in the RT field were 60% and 100 %, respectively. All 4 patients who underwent surgery had no evidence of disease in the RT field. Of the 5 patients who received RT to the primary gross tumor, 1 had complete response, 2 had partial response, and 2 had stable disease in the RT field. The median time to progression was 11 months. Of the 9 patients, four patients had no progression, and 5 patients had progression of disease (locoregional, 2; distant, 2; locoregional/distant, 1). Of the 4 patients without progression, 3 were treated with RT in adjuvant or neoadjuvant setting, and one received RT to primary tumor. One patient experienced radiation-induced duodenitis at 3 months after concurrent chemoradiation without treatment-related mortality. Conclusion: RT can yield local control for advanced PB-NETs. RT should be considered an essential part of multimodality treatment in management of advanced PB-NETs.

UR - http://www.scopus.com/inward/record.url?scp=84885818448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885818448&partnerID=8YFLogxK

U2 - 10.3857/roj.2013.31.3.125

DO - 10.3857/roj.2013.31.3.125

M3 - Article

C2 - 24137557

AN - SCOPUS:84885818448

VL - 31

SP - 125

EP - 130

JO - Radiation Oncology Journal

JF - Radiation Oncology Journal

SN - 2234-1900

IS - 3

ER -